Steatotic liver disease is the most important somatic determinant of quality of life in patients with obesity: A cross-sectional study.

التفاصيل البيبلوغرافية
العنوان:	Steatotic liver disease is the most important somatic determinant of quality of life in patients with obesity: A cross-sectional study.
المؤلفون:	Wernberg CW; Liver Research Group, Department of Gastroenterology and Hepatology, University Hospital of South Denmark, Esbjerg, Denmark.; ATLAS Center for Functional Genomics and Tissue Plasticity, University of Southern Denmark, Odense, Denmark., Kjer MF; Liver Research Group, Department of Gastroenterology and Hepatology, University Hospital of South Denmark, Esbjerg, Denmark.; OPEN Open Patient Data Explorative Network, Odense, Denmark., Grønkjaer LL; Liver Research Group, Department of Gastroenterology and Hepatology, University Hospital of South Denmark, Esbjerg, Denmark.; OPEN Open Patient Data Explorative Network, Odense, Denmark., Jacobsen BG; Liver Research Group, Department of Gastroenterology and Hepatology, University Hospital of South Denmark, Esbjerg, Denmark.; OPEN Open Patient Data Explorative Network, Odense, Denmark., Lauridsen MM; Liver Research Group, Department of Gastroenterology and Hepatology, University Hospital of South Denmark, Esbjerg, Denmark.; ATLAS Center for Functional Genomics and Tissue Plasticity, University of Southern Denmark, Odense, Denmark.
المصدر:	Liver international : official journal of the International Association for the Study of the Liver [Liver Int] 2024 Jan; Vol. 44 (1), pp. 191-201. Date of Electronic Publication: 2023 Oct 30.
نوع المنشور:	Journal Article; Research Support, Non-U.S. Gov't
اللغة:	English
بيانات الدورية:	Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 101160857 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1478-3231 (Electronic) Linking ISSN: 14783223 NLM ISO Abbreviation: Liver Int Subsets: MEDLINE
أسماء مطبوعة:	Publication: Malden, MA : Wiley-Blackwell Original Publication: Oxford, UK : Blackwell Munksgaard, c2003-
مواضيع طبية MeSH:	Quality of Life* , Fatty Liver*/epidemiology, Humans ; Female ; Middle Aged ; Male ; Cross-Sectional Studies ; Obesity/complications ; Obesity/epidemiology
مستخلص:	Background and Aims: Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) are often comorbid and stigmatized. This can negatively affect quality of life (QOL). Other studies have primarily used the Chronic Liver Disease Questionnaire (CLDQ), which focuses on liver-related symptoms, to characterize QOL, but most MASLD patients have only mild liver disease, and CLDQ might overlook QOL issues pertaining to them. We aimed to determine the impact of metabolic dysfunction-associated steatohepatitis (MASH) on QOL in obese patients using a 136-item generic QOL questionnaire. Methods: We included participants with BMI ≥ 35 kg/m ² who all fully answered the sickness impact profile (SIP, range 0-100, normal = 3.4, 100 = worst) and had a liver biopsy to diagnose MASLD. Sociodemographics, comorbidity and biometric data were obtained from all participants. Results: Of 176 (mean age 45.9 years, 70% female, 12.6 years of education), 132 had no-MASH and 44 MASH. On stepwise multivariable regression analysis, divorce (p = .011), unemployment (p < .003) and hepatic steatosis (p = .01) were associated with poor overall QOL. No other somatic comorbidity was associated. MASH patients more frequently than no-MASH reported physical discomfort (48% vs. 30%, p = .04), inability to do daily activities (29% vs. 54%, p = .006) and attention problems (32% vs. 57%, p = .003). Conclusion: MASLD severity was the only somatic determinant of QOL in patients with obesity in this cohort, and a large fraction reported debilitating symptoms. Patients and caregivers should consider the limitations this poses when planning interventions. (© 2023 The Authors. Liver International published by John Wiley & Sons Ltd.)
References:	Engin A. The definition and prevalence of obesity and metabolic syndrome. Adv Exp Med Biol. 2017;960:1-17. doi:10.1007/978-3-319-48382-5_1. Milić S, Lulić D, Štimac D. Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. World J Gastroenterol. 2014;20(28):9330-9337. doi:10.3748/wjg.v20.i28.9330. Rosato V, Masarone M, Dallio M, Federico A, Aglitti A, Persico M. NAFLD and extra-hepatic comorbidities: current evidence on a multi-organ metabolic syndrome. Int J Environ Res Public Health. 2019;16(18):3415. doi:10.3390/ijerph16183415. Rinella ME, Lazarus JV, Ratziu V, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023. doi:10.1016/j.jhep.2023.06.003. Manne V, Handa P, Kowdley KV. Pathophysiology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Clin Liver Dis. 2018;22(1):23-37. doi:10.1016/j.cld.2017.08.007. Caligiuri A, Gentilini A, Marra F. Molecular pathogenesis of NASH. Int J Mol Sci. 2016;17(9):1575. doi:10.3390/ijms17091575. Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44(4):865-873. doi:10.1002/hep.21327. Wong VW, Wong GL, Choi PC, et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut. 2010;59(7):969-974. doi:10.1136/gut.2009.205088. Younossi Z, Golabi P, Paik J, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;1097:10. Ward ZJ, Bleich SN, Cradock AL, et al. Projected U.S. state-level prevalence of adult obesity and severe obesity. N Engl J Med. 2019;381(25):2440-2450. doi:10.1056/NEJMsa1909301. Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, al Kaabi J. Epidemiology of type 2 diabetes - global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020;10(1):107-111. doi:10.2991/jegh.k.191028.001. Ge X, Zheng L, Wang M, Du Y, Jiang J. Prevalence trends in non-alcoholic fatty liver disease at the global, regional and national levels, 1990-2017: a population-based observational study. BMJ Open. 2020;10(8):e036663. doi:10.1136/bmjopen-2019-036663. Kennedy-Martin T, Bae JP, Paczkowski R, Freeman E. Health-related quality of life burden of nonalcoholic steatohepatitis: a robust pragmatic literature review. J Patient Rep Outcomes. 2018;2(1):28. doi:10.1186/s41687-018-0052-7. Dan AA, Kallman JB, Wheeler A, et al. Health-related quality of life in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2007;26(6):815-820. doi:10.1111/j.1365-2036.2007.03426.x. David K, Kowdley KV, Unalp A, et al. Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network. Hepatology. 2009;49(6):1904-1912. doi:10.1002/hep.22868. Huber Y, Boyle M, Hallsworth K, et al. Health-related quality of life in nonalcoholic fatty liver disease associates with hepatic inflammation. Clin Gastroenterol Hepatol. 2019;17(10):2085-92.e1. doi:10.1016/j.cgh.2018.12.016. Golabi P, Otgonsuren M, Cable R, et al. Non-alcoholic fatty liver disease (NAFLD) is associated with impairment of health related quality of life (HRQOL). Health Qual Life Outcomes. 2016;14:18. doi:10.1186/s12955-016-0420-z. Younossi Z, Aggarwal P, Shrestha I, et al. The burden of non-alcoholic steatohepatitis: a systematic review of health-related quality of life and patient-reported outcomes. JHEP Rep. 2022;4(9):100525. doi:10.1016/j.jhepr.2022.100525. Indira Chandran V, Wernberg CW, Lauridsen MM, et al. Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness. Hepatology. 2022;77:558-572. doi:10.1002/hep.32620. Lauridsen MM, Jepsen P, Wernberg CW, Schaffalitzky de Muckadell OB, Bajaj JS, Vilstrup H. Validation of a simple quality-of-life score for identification of minimal and prediction of overt hepatic encephalopathy. Hepatol Commun. 2020;4(9):1353-1361. doi:10.1002/hep4.1555. Vega GL. Results of expert meetings: obesity and cardiovascular disease. Obesity, the metabolic syndrome, and cardiovascular disease. Am Heart J. 2001;142(6):1108-1116. doi:10.1067/mhj.2001.119790. de Muckadell OBS, von Arenstorff Vilstrup JHSH. Medicinsk Kompendium. Munksgaard; 2019. Jacobs HM, Luttik A, Touw-Otten FW, de Melker RA. De 'sickness impact profile'; resultaten van een valideringsonderzoek van de Nederlandse versie. Ned Tijdschr Geneeskd. 1990;134:1950-1954. Groeneweg M, Quero JC, De Bruijn I, et al. Subclinical hepatic encephalopathy impairs daily functioning. Hepatology. 1998;28(1):45-49. doi:10.1002/hep.510280108. Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology. 2007;45(3):549-559. doi:10.1002/hep.21533. Mittal VV, Sharma BC, Sharma P, Sarin SK. A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol. 2011;23(8):725-732. doi:10.1097/MEG.0b013e32834696f5. Nabi E, Thacker LR, Wade JB, et al. Diagnosis of covert hepatic encephalopathy without specialized tests. Clin Gastroenterol Hepatol. 2014;12(8):1384-89.e2. doi:10.1016/j.cgh.2013.12.020. Bech P, Rasmussen NA, Olsen LR, Noerholm V, Abildgaard W. The sensitivity and specificity of the Major Depression Inventory, using the Present State Examination as the index of diagnostic validity. J Affect Disord. 2001;66(2-3):159-164. doi:10.1016/s0165-0327(00)00309-8. Bergner M, Bobbitt RA, Carter WB, Gilson BS. The sickness impact profile: development and final revision of a health status measure. Med Care. 1981;19(8):787-805. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208. doi:10.1016/j.jbi.2019.103208. Seo SW, Gottesman RF, Clark JM, et al. Nonalcoholic fatty liver disease is associated with cognitive function in adults. Neurology. 2016;86(12):1136-1142. doi:10.1212/WNL.0000000000002498. Yu Q, He R, Jiang H, et al. Association between metabolic dysfunction-associated fatty liver disease and cognitive impairment. J Clin Transl Hepatol. 2022;10(6):1034-1041. doi:10.14218/jcth.2021.00490. Ren ZL, Li CX, Ma CY, et al. Linking nonalcoholic fatty liver disease and brain disease: focusing on bile acid signaling. Int J Mol Sci. 2022;23(21):13045. doi:10.3390/ijms232113045. Mikkelsen ACD, Kjaergaard K, Mookerjee RP, et al. Non-alcoholic fatty liver disease: also a disease of the brain? A systematic review of the preclinical evidence. Neurochem Res. 2022. doi:10.1007/s11064-022-03551-x. Kjaergaard K, Mikkelsen ACD, Wernberg CW, et al. Cognitive dysfunction in non-alcoholic fatty liver disease-current knowledge, mechanisms and perspectives. J Clin Med. 2021;10(4):673. doi:10.3390/jcm10040673. Zhu Y, Wang NN, Pan D, Wang S. Risk of overweight and obesity in children and adolescents with attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. Child Obes. 2023. doi:10.1089/chi.2022.0230. Kanarik M, Grimm O, Mota NR, Reif A, Harro J. ADHD co-morbidities: a review of implication of gene × environment effects with dopamine-related genes. Neurosci Biobehav Rev. 2022;139:104757. doi:10.1016/j.neubiorev.2022.104757. Kittel-Schneider S, Arteaga-Henriquez G, Vasquez AA, et al. Non-mental diseases associated with ADHD across the lifespan: Fidgety Philipp and Pippi Longstocking at risk of multimorbidity? Neurosci Biobehav Rev. 2022;132:1157-1180. doi:10.1016/j.neubiorev.2021.10.035.
معلومات مُعتمدة:	DNRF141 Danish National Research Foundation
فهرسة مساهمة:	Keywords: fatty liver; non-alcoholic fatty liver disease; obesity; quality of life; sickness impact profile
تواريخ الأحداث:	Date Created: 20231031 Date Completed: 20231220 Latest Revision: 20240319
رمز التحديث:	20240319
DOI:	10.1111/liv.15761
PMID:	37904634
قاعدة البيانات:	MEDLINE

View record at Wiley

Full Text Finder

الوصف
تدمد:	1478-3231
DOI:	10.1111/liv.15761